Atlas Trials

A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer

Clinical trial NCT07679360 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07679360
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2026-07-01
Primary completion
2030-12-01
Enrollment
1000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.